文献速递肿瘤 PET/CT神经核医学

胃旁路术后低血糖患者18F-FDOPA PET/CT胰腺摄取与对照组比较:伴或不伴卡比多巴预处理

Pancreatic Uptake by 18F-FDOPA PET/CT in Patients With Hypoglycemia After Gastric Bypass Surgery Compared With Controls With or Without Carbidopa Pretreatment.
PubMed 文献 · Clin Nucl Med · 2017-01-01

回顾性分析2009至2015年大学医学中心18F-FDOPA PET/CT扫描,比较无胰腺疾病者(344例接受卡比多巴预处理、14例未接受)与胃旁路术后低血糖患者(9例)的胰腺SUVmax。卡比多巴预处理者胰腺各区域中位SUVmax较低(均P<0.01);胃旁路术后低血糖未预处理者胰腺各区域中位SUVmax高于未预处理对照(均P<0.03)。结论认为胃旁路术后低血糖患者胰腺各区摄取增高,卡比多巴预处理可降低非病变胰腺摄取、可能掩盖疾病活动。

要点

  • 卡比多巴预处理者胰腺头、体、尾中位SUVmax较未预处理者低(分别-1.15、-1.20、-0.84,均P<0.01)。
  • 胃旁路术后低血糖未预处理者胰腺头、体、尾中位SUVmax较未预处理对照高(分别+1.18、+1.39、+1.63,均P<0.03)。
  • 作者认为卡比多巴预处理可降低非病变胰腺18F-FDOPA摄取,可能因此掩盖胃旁路术后低血糖的疾病活动。

核心结论

  • 胃旁路术后低血糖患者胰腺所有区域18F-FDOPA摄取增高。
  • 卡比多巴预处理降低非病变胰腺18F-FDOPA摄取,可能因此掩盖胃旁路术后低血糖的疾病活动。

研究设计与样本

  • 回顾性数据分析,纳入2009至2015年大学医学中心18F-FDOPA PET/CT扫描,按欧洲核医学协会/EANM Research Ltd指南重建和计算。
  • 无胰腺疾病或低血糖疾病者358例中344例接受卡比多巴预处理、14例未接受;另9例为胃旁路术后低血糖患者。

主要发现

  • 卡比多巴预处理患者胰腺头、体、尾中位SUVmax较未预处理患者分别低1.15、1.20、0.84(均P<0.01)。
  • 胃旁路术后低血糖未预处理患者胰腺头、体、尾中位SUVmax较未预处理对照分别高1.18、1.39、1.63(均P<0.03)。

关键数值与推荐

  • 主要结局指标为胰腺头、体、尾区域的18F-FDOPA SUVmax。
  • 原文指出,在疑为胰腺疾病所致低血糖患者中使用18F-FDOPA PET/CT有助于定位胰岛素过量产生来源,在此情形下不推荐卡比多巴预处理。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The use of Fluorine-labeled dihydroxy-phenyl-alanine (F-FDOPA) PET/CT in patients with hypoglycemia suspected to be caused by pancreatic disease can be helpful to localize the source of excess insulin production. In this setting, carbidopa pretreatment is not recommended. However, quantitative comparisons of pancreatic tracer uptake in patients with or without carbidopa pretreatment and in diffuse pancreatic disease are lacking. Therefore, we aimed to describe and quantify pancreatic F-FDOPA uptake in patients without pancreatic disease with or without carbidopa pretreatment and in patients with hypoglycemia after gastric bypass surgery. PATIENTS AND METHODS: This is a retrospective data analysis of F-FDOPA PET/CT scans performed at a university medical center in the period from 2009 to 2015. All scans were reconstructed and calculated based on the European Association of Nuclear Medicine/EANM Research Ltd guidelines. Of 358 patients without evidence of pancreatic disease or hypoglycemic disorders, 344 received carbidopa and 14 did not. Another 9 patients had post-gastric bypass hypoglycemia. The main outcome measurement was F-FDOPA SUVmax for pancreatic head, body, and tail regions. RESULTS: Carbidopa pretreated patients had a lower median SUVmax (-1.15, -1.20, and -0.84 in pancreatic head, body, and tail [all P < 0.01]) than patients without carbidopa pretreatment. Patients with post-gastric bypass hypoglycemia scanned without carbidopa pretreatment had higher median SUVmax (+1.18, +1.39, and +1.63, all P < 0.03) compared with controls without pretreatment. CONCLUSIONS: Patients with post-gastric bypass hypoglycemia have increased uptake in all pancreatic regions. Carbidopa pretreatment lowers pancreatic F-FDOPA uptake in the nonaffected pancreas and may therefore mask disease activity in post-gastric bypass hypoglycemia.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. van Beek AP, de Heide LJ, van Ginkel B, et al. Pancreatic Uptake by 18F-FDOPA PET/CT in Patients With Hypoglycemia After Gastric Bypass Surgery Compared With Controls With or Without Carbidopa Pretreatment. Clin Nucl Med. 2017. PMID: 28005639. doi:10.1097/RLU.0000000000001496

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。